Acarbose (Glucobay, BAYG5421)
DrugPatients with diabetes type 2 newly treated with Glucobay
NCT Number: NCT00909051
Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Multiple Locations, Algeria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients with diabetes type 2 newly treated with Glucobay
Time frame: During observation period of three months
Bayer
Industry
Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial DetailsNCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07728162
Diabetes Mellitus, Disease Attributes
Bolu, Turkey (Türkiye)
View Trial Details